Literature DB >> 24389139

Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.

Nitin Jain1, Susan O'Brien1, Deborah Thomas1, Hagop Kantarjian1.   

Abstract

Antibody-drug conjugates (ADCs) represent a major advance in the treatment of acute lymphoblastic leukemia (ALL). CD22 expression, seen in majority of patients with B-lineage ALL, is an ideal target for ADCs. Inotuzumab ozogamicin is an ADC comprised of a humanized IgG4 monoclonal antibody covalently linked to calecheamicin. Inotuzumab ozogamicin has shown promising single-agent activity in patients with ALL and in CD22 positive non-Hodgkin lymphoma. Studies exploring the combination of inotuzumab ozogamicin with chemotherapy are ongoing.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24389139     DOI： 10.2741/e688

Source DB:  PubMed          Journal:  Front Biosci (Elite Ed)        ISSN： 1945-0494


  6 in total

1.  Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study.

Authors:  Daniel J DeAngelo; Wendy Stock; Anthony S Stein; Andrei Shustov; Michaela Liedtke; Charles A Schiffer; Erik Vandendries; Katherine Liau; Revathi Ananthakrishnan; Joseph Boni; A Douglas Laird; Luke Fostvedt; Hagop M Kantarjian; Anjali S Advani
Journal:  Blood Adv       Date:  2017-06-27

Review 2.  Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia.

Authors:  Binsah George; Hagop Kantarjian; Elias Jabbour; Nitin Jain
Journal:  Immunotherapy       Date:  2016-01-18       Impact factor: 4.196

Review 3.  Recent advances and novel treatment paradigms in acute lymphocytic leukemia.

Authors:  Nikolaos Papadantonakis; Anjali S Advani
Journal:  Ther Adv Hematol       Date:  2016-06-29

4.  Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

Authors:  Hagop M Kantarjian; Daniel J DeAngelo; Matthias Stelljes; Giovanni Martinelli; Michaela Liedtke; Wendy Stock; Nicola Gökbuget; Susan O'Brien; Kongming Wang; Tao Wang; M Luisa Paccagnella; Barbara Sleight; Erik Vandendries; Anjali S Advani
Journal:  N Engl J Med       Date:  2016-06-12       Impact factor: 91.245

Review 5.  Altered tumor-cell glycosylation promotes metastasis.

Authors:  Irina Häuselmann; Lubor Borsig
Journal:  Front Oncol       Date:  2014-02-13       Impact factor: 6.244

Review 6.  Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics.

Authors:  Eunhee G Kim; Kristine M Kim
Journal:  Biomol Ther (Seoul)       Date:  2015-11-01       Impact factor: 4.634
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.